Skip to main content

Table 1 Patient characteristics

From: Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing

Characteristics n = 21
Age Median 68 (38–84)
Gender
 Male 12 (57%)
 Female 9 (43%)
Primary tumour location
 Right 9 (43%)
 Left 12 (57%)
Resection
 Concurrent 5 (24%)
 Subsequent – liver first 5 (24%)
 Subsequent – primary first 11 (52%)
Time between resections Median 36 days
Treatment
 Chemonaïve 11 (52%)
 Both tumours 7 (33%)
 Only metastasis 2 (10%)
 Only primary 1 (5%)
Neoadjuvant treatment
 CAPOX 2 (10%)
 CAPOX + bevacizumab 2 (10%)
 FOLFIRI + cetuximab 1 (5%)
 FOLFOX + cetuximab 2 (10%)
Between resections
 CAPOX 2 (10%)
 FOLFOX 1 (5%)
Number metastases Median 2 (1–5)
Microsatellite stability 21 (100%)
Tumour stage
 Stage IV 21 (100%)
Tumour differentiation
 Low 2 (10%)
 High 19 (90%)
  1. CAPOX denotes capecitabine and oxaliplatin, FOLFIRI signifies 5-fluorouracil and irinotecan; and FOLFOX indicates 5-fluorouracil and oxaliplatin
\